Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.45 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 5.00 billion
Earnings per share -0.003
Dividend per share N/A
Year To Date Return 195.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Imugene Ltd (ASX: IMU)
Latest News

IMU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Imugene Ltd

Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.

IMU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
30 Jul 2021 $0.30 $-0.01 -3.33% 16,405,949 $0.30 $0.31 $0.30
29 Jul 2021 $0.30 $-0.03 -9.09% 57,302,849 $0.30 $0.31 $0.29
26 Jul 2021 $0.33 $-0.01 -2.99% 5,471,664 $0.34 $0.34 $0.33
23 Jul 2021 $0.34 $-0.02 -5.71% 5,157,300 $0.35 $0.35 $0.34
22 Jul 2021 $0.35 $0.01 2.94% 12,843,037 $0.34 $0.36 $0.34
21 Jul 2021 $0.34 $0.03 9.52% 9,413,757 $0.32 $0.34 $0.32
20 Jul 2021 $0.32 $-0.01 -3.08% 8,862,333 $0.32 $0.33 $0.31
19 Jul 2021 $0.33 $-0.01 -2.99% 13,629,557 $0.34 $0.34 $0.32
16 Jul 2021 $0.34 $-0.01 -2.94% 7,050,215 $0.33 $0.34 $0.33
15 Jul 2021 $0.34 $0.01 3.03% 5,244,500 $0.33 $0.34 $0.33
14 Jul 2021 $0.33 $-0.01 -2.94% 6,809,854 $0.34 $0.34 $0.33
13 Jul 2021 $0.34 $0.01 3.03% 4,204,753 $0.34 $0.34 $0.33
12 Jul 2021 $0.33 $0.00 0.00% 8,546,905 $0.34 $0.35 $0.33
09 Jul 2021 $0.33 $0.00 0.00% 4,625,535 $0.33 $0.34 $0.33
08 Jul 2021 $0.33 $-0.01 -2.99% 5,793,083 $0.34 $0.34 $0.33
07 Jul 2021 $0.34 $0.00 0.00% 8,159,555 $0.34 $0.35 $0.33
06 Jul 2021 $0.34 $-0.02 -5.71% 14,187,793 $0.36 $0.36 $0.33
05 Jul 2021 $0.35 $-0.02 -5.48% 12,276,054 $0.38 $0.38 $0.35

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
01 Jul 2021 Lesley Russell Buy 15 $630,000
Exercise of options.
01 Jul 2021 Lesley Russell Exercise 15 $630,000
Exercise of options.
01 Jul 2021 Lesley Russell Sell 1 $629,080
On-market trade.
28 May 2021 Leslie (Mi Ok) Chong Exercise 13 $623,000
Exercise of options.
28 May 2021 Leslie (Mi Ok) Chong Buy 13 $623,000
Exercise of options.
26 May 2021 Paul Hopper Sell 1 $702,339
On-market trade.
26 May 2021 Paul Hopper Exercise 25 $1,125,000
Exercise of options.
26 May 2021 Paul Hopper Buy 25 $1,125,000
Exercise of options.
25 May 2021 Leslie (Mi Ok) Chong Sell 4 $1,648,431
On-market trade.
25 May 2021 Leslie (Mi Ok) Chong Exercise 36 $1,627,000
Exercise of options.
25 May 2021 Leslie (Mi Ok) Chong Buy 36 $1,627,000
Exercise of options.
21 May 2021 Charles Walker Sell 3 $1,236,500
On-market trade.
22 Dec 2020 Leslie (Mi Ok) Chong Exercise 98 $3,950
Exercise of options.
22 Dec 2020 Leslie (Mi Ok) Chong Buy 98 $3,950
Exercise of options.
22 Dec 2020 Paul Hopper Exercise 827 $33,091
Exercise of options.
22 Dec 2020 Paul Hopper Buy 827 $33,091
Exercise of options.
16 Dec 2020 Axel Hoos Exercise 15 $620,000
Exercise of options.
16 Dec 2020 Axel Hoos Buy 15 $620,000
Exercise of options.
11 Dec 2020 Axel Hoos Sell 3 $345,300
On-market trade.
01 Dec 2020 Charles Walker Buy 325 $8,450
Exercise of options.
01 Dec 2020 Charles Walker Exercise 123 $4,938
Exercise of options.
01 Dec 2020 Charles Walker Buy 49 $1,287
Exercise of options.
01 Dec 2020 Charles Walker Exercise 49 $1,287
Exercise of options.
01 Dec 2020 Charles Walker Exercise 325 $8,450
Exercise of options.
01 Dec 2020 Charles Walker Buy 123 $4,938
Exercise of options.
01 Dec 2020 Charles Walker Sell 7 $952,500
On-market trade.
10 Aug 2020 Charles Walker Sell 4 $260,100
On-market trade.
04 Aug 2020 Leslie (Mi Ok) Chong Buy 27 $405,000
Exercise of options.
04 Aug 2020 Leslie (Mi Ok) Chong Exercise 27 $405,000
Exercise of options.
04 Aug 2020 Charles Walker Sell 82 $4,785
On-market trade.
04 Aug 2020 Charles Walker Buy 49 $2,871
On-market trade.
04 Aug 2020 Axel Hoos Sell 10 $540,000
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
Ms Chong has over 21 years' experience in leading clinical and department development in oncology. She is Director of Cure Brain Cancer Foundation since April 2020.
Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
Mr Hopper has over 20 years' experience in the management and funding of biotechnology and health care public companies both as chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas and on immune therapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.
Mr Charles Walker Non-Executive Director Jan 2015
Mr Walker has experience across the biotechnology and life sciences industry. His experience includes operational and leadership positions in biotechnology firms, capital markets track record from executing nearly 60 international and domestic corporate transactions, both as principal and advisor, and a detailed scientific understanding from a technical background in pharmacology. He is Chair of Risk Committee.
Dr Axel Hoos Non-Executive Director Dec 2013
Dr Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). At GSK he leads technical and funding decisions in R&D as well as Discovery and Development in Oncology and in immuno-oncology, epigenetics, cell therapy, and synthetic lethality. Dr Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), Director on the Board of TCR2, Co-Founder and Director on the Board of Imugene, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipitimumab). Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (former Antigenics). He is Member of Risk Committee.
Dr Lesley Russell Non-Executive Director Apr 2019
Dr Russell has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK.
Dr Jens Eckstein Non-Executive Director May 2019
Dr Eckstein has more than 15 years' venture capital experience in the biopharmaceutical industry and 10 years' operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at NM Capital. He is Member of Risk Committee.
Mr Phillip Hains Chief Financial OfficerJoint Company Secretary Dec 2012
-
Mr Justyn Peter Stedwell Company Secretary
-
Phillip Hains Chief Financial OfficerJoint Company Secretary
-
Mark Marino Chief Medical Officer
-
Nicholas Ede Chief Technology Officer
-
Justyn Peter Stedwell Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Richard John Mann 143,350,000 3.27%
National Nominees Limited 132,225,469 3.02%
Dr Nicholas Smith 118,000,000 2.69%
Paul Hopper 76,178,722 1.74%
Citicorp Nominees Pty Limited 72,441,684 1.65%
Hsbc Custody Nominees (Australia) Limited 71,548,850 1.63%
Mann Beef Pty Ltd 65,000,000 1.48%
Sarah Cameron 60,000,000 1.37%
Netwealth Investments Limited 56,543,463 1.29%
J P Morgan Nominees Australia Pty Limited 40,119,975 0.92%
Mr Andrew John Kempson 34,921,053 0.80%
Mr Dale Anthony Reed 32,000,000 0.73%
Mi Ok Chong 31,387,124 0.72%
Mr Andrew Murray Gregor 27,700,000 0.63%
Dr Roger Aston 27,562,500 0.63%
Mrs Yasmin Marie Dennis Mann 23,646,995 0.54%
Strategic Vision Equities P L 23,000,000 0.53%
BNP Paribas Nominees Pty Ltd 22,579,451 0.52%
Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin 22,000,000 0.50%
John Dahlsen Superannuation Fund Pty Ltd 21,666,142 0.50%

Profile

since

Note